[
    [
        {
            "time": "",
            "original_text": "掉队公司后来居上：微芯生物发行价20.43元 周三打新",
            "features": {
                "keywords": [
                    "微芯生物",
                    "发行价",
                    "打新"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "掉队公司后来居上：微芯生物发行价20.43元 周三打新",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "复宏汉霖“融资研发”模式恐难长久 多款产品面临“夹击”",
            "features": {
                "keywords": [
                    "复宏汉霖",
                    "融资研发",
                    "产品夹击"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "复宏汉霖“融资研发”模式恐难长久 多款产品面临“夹击”",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "96个注射剂“搅局”6000亿市场 33个品种年销超10亿",
            "features": {
                "keywords": [
                    "注射剂",
                    "市场",
                    "品种"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "96个注射剂“搅局”6000亿市场 33个品种年销超10亿",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "事件驱动型量化基金，能长期跑赢市场吗？",
            "features": {
                "keywords": [
                    "事件驱动",
                    "量化基金",
                    "跑赢市场"
                ],
                "sentiment_score": 0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "事件驱动型量化基金，能长期跑赢市场吗？",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "【中信建投医药|行业周报】：行业增速平稳，关注科创方向",
            "features": {
                "keywords": [
                    "中信建投",
                    "医药",
                    "行业周报",
                    "科创方向"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【中信建投医药|行业周报】：行业增速平稳，关注科创方向",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "以辅仁药业为例，谈暴雷迹象的认定与否定",
            "features": {
                "keywords": [
                    "辅仁药业",
                    "暴雷",
                    "迹象"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "以辅仁药业为例，谈暴雷迹象的认定与否定",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业跨市场周报:医药科创板“首秀”靓丽，选择优质公司是关键",
            "features": {
                "keywords": [
                    "医药生物",
                    "科创板",
                    "首秀",
                    "优质公司"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业跨市场周报:医药科创板“首秀”靓丽，选择优质公司是关键",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]